These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
330 related articles for article (PubMed ID: 20603437)
1. A let-7 microRNA-binding site polymorphism in 3'-untranslated region of KRAS gene predicts response in wild-type KRAS patients with metastatic colorectal cancer treated with cetuximab monotherapy. Zhang W; Winder T; Ning Y; Pohl A; Yang D; Kahn M; Lurje G; LaBonte MJ; Wilson PM; Gordon MA; Hu-Lieskovan S; Mauro DJ; Langer C; Rowinsky EK; Lenz HJ Ann Oncol; 2011 Jan; 22(1):104-109. PubMed ID: 20603437 [TBL] [Abstract][Full Text] [Related]
2. Let-7 miRNA-binding site polymorphism in the KRAS 3'UTR; colorectal cancer screening population prevalence and influence on clinical outcome in patients with metastatic colorectal cancer treated with 5-fluorouracil and oxaliplatin +/- cetuximab. Kjersem JB; Ikdahl T; Guren T; Skovlund E; Sorbye H; Hamfjord J; Pfeiffer P; Glimelius B; Kersten C; Solvang H; Tveit KM; Kure EH BMC Cancer; 2012 Nov; 12():534. PubMed ID: 23167843 [TBL] [Abstract][Full Text] [Related]
3. Genetic modulation of the Let-7 microRNA binding to KRAS 3'-untranslated region and survival of metastatic colorectal cancer patients treated with salvage cetuximab-irinotecan. Graziano F; Canestrari E; Loupakis F; Ruzzo A; Galluccio N; Santini D; Rocchi M; Vincenzi B; Salvatore L; Cremolini C; Spoto C; Catalano V; D'Emidio S; Giordani P; Tonini G; Falcone A; Magnani M Pharmacogenomics J; 2010 Oct; 10(5):458-64. PubMed ID: 20177422 [TBL] [Abstract][Full Text] [Related]
4. A let-7 microRNA-binding site polymorphism in KRAS predicts improved outcome in patients with metastatic colorectal cancer treated with salvage cetuximab/panitumumab monotherapy. Saridaki Z; Weidhaas JB; Lenz HJ; Laurent-Puig P; Jacobs B; De Schutter J; De Roock W; Salzman DW; Zhang W; Yang D; Pilati C; Bouché O; Piessevaux H; Tejpar S Clin Cancer Res; 2014 Sep; 20(17):4499-4510. PubMed ID: 25183481 [TBL] [Abstract][Full Text] [Related]
5. The LCS6 polymorphism in the binding site of let-7 microRNA to the KRAS 3'-untranslated region: its role in the efficacy of anti-EGFR-based therapy in metastatic colorectal cancer patients. Sebio A; Paré L; Páez D; Salazar J; González A; Sala N; del Río E; Martín-Richard M; Tobeña M; Barnadas A; Baiget M Pharmacogenet Genomics; 2013 Mar; 23(3):142-7. PubMed ID: 23324806 [TBL] [Abstract][Full Text] [Related]
6. Germline polymorphisms in genes involved in the IGF1 pathway predict efficacy of cetuximab in wild-type KRAS mCRC patients. Winder T; Zhang W; Yang D; Ning Y; Bohanes P; Gerger A; Wilson PM; Pohl A; Mauro DJ; Langer C; Rowinsky EK; Lenz HJ Clin Cancer Res; 2010 Nov; 16(22):5591-602. PubMed ID: 20935157 [TBL] [Abstract][Full Text] [Related]
7. KRAS let-7 LCS6 SNP predicts cetuximab efficacy in KRASwt metastatic colorectal cancer patients: Does treatment combination partner matter? Zhang W; Labonte MJ; Lenz HJ Ann Oncol; 2011 Feb; 22(2):484-5. PubMed ID: 21278223 [No Abstract] [Full Text] [Related]
8. Let-7 microRNA-binding-site polymorphism in the 3'UTR of KRAS and colorectal cancer outcome: a systematic review and meta-analysis. Langevin SM; Christensen BC Cancer Med; 2014 Oct; 3(5):1385-95. PubMed ID: 24890702 [TBL] [Abstract][Full Text] [Related]
9. Activating KRAS mutations and overexpression of epidermal growth factor receptor as independent predictors in metastatic colorectal cancer patients treated with cetuximab. Yen LC; Uen YH; Wu DC; Lu CY; Yu FJ; Wu IC; Lin SR; Wang JY Ann Surg; 2010 Feb; 251(2):254-60. PubMed ID: 20010090 [TBL] [Abstract][Full Text] [Related]
10. Markers for EGFR pathway activation as predictor of outcome in metastatic colorectal cancer patients treated with or without cetuximab. Tol J; Dijkstra JR; Klomp M; Teerenstra S; Dommerholt M; Vink-Börger ME; van Cleef PH; van Krieken JH; Punt CJ; Nagtegaal ID Eur J Cancer; 2010 Jul; 46(11):1997-2009. PubMed ID: 20413299 [TBL] [Abstract][Full Text] [Related]
11. Association study of the let-7 miRNA-complementary site variant in the 3' untranslated region of the KRAS gene in stage III colon cancer (NCCTG N0147 Clinical Trial). Sha D; Lee AM; Shi Q; Alberts SR; Sargent DJ; Sinicrope FA; Diasio RB Clin Cancer Res; 2014 Jun; 20(12):3319-27. PubMed ID: 24727325 [TBL] [Abstract][Full Text] [Related]
12. Correlation of FCGR3A and EGFR germline polymorphisms with the efficacy of cetuximab in KRAS wild-type metastatic colorectal cancer. Pander J; Gelderblom H; Antonini NF; Tol J; van Krieken JH; van der Straaten T; Punt CJ; Guchelaar HJ Eur J Cancer; 2010 Jul; 46(10):1829-34. PubMed ID: 20418097 [TBL] [Abstract][Full Text] [Related]
13. Prognostic role of the LCS6 KRAS variant in locally advanced rectal cancer: results of the EXPERT-C trial. Sclafani F; Chau I; Cunningham D; Peckitt C; Lampis A; Hahne JC; Braconi C; Tabernero J; Glimelius B; Cervantes A; Begum R; Gonzalez De Castro D; Hulkki Wilson S; Eltahir Z; Wotherspoon A; Tait D; Brown G; Oates J; Valeri N Ann Oncol; 2015 Sep; 26(9):1936-1941. PubMed ID: 26162609 [TBL] [Abstract][Full Text] [Related]
14. KRAS p.G13D mutation and codon 12 mutations are not created equal in predicting clinical outcomes of cetuximab in metastatic colorectal cancer: a systematic review and meta-analysis. Mao C; Huang YF; Yang ZY; Zheng DY; Chen JZ; Tang JL Cancer; 2013 Feb; 119(4):714-21. PubMed ID: 22972628 [TBL] [Abstract][Full Text] [Related]
15. Role of KRAS let-7 LCS6 SNP in metastatic colorectal cancer patients. Ruzzo A; Canestrari E; Galluccio N; Santini D; Vincenzi B; Tonini G; Magnani M; Graziano F Ann Oncol; 2011 Jan; 22(1):234-235. PubMed ID: 20926546 [No Abstract] [Full Text] [Related]
16. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. De Roock W; Claes B; Bernasconi D; De Schutter J; Biesmans B; Fountzilas G; Kalogeras KT; Kotoula V; Papamichael D; Laurent-Puig P; Penault-Llorca F; Rougier P; Vincenzi B; Santini D; Tonini G; Cappuzzo F; Frattini M; Molinari F; Saletti P; De Dosso S; Martini M; Bardelli A; Siena S; Sartore-Bianchi A; Tabernero J; Macarulla T; Di Fiore F; Gangloff AO; Ciardiello F; Pfeiffer P; Qvortrup C; Hansen TP; Van Cutsem E; Piessevaux H; Lambrechts D; Delorenzi M; Tejpar S Lancet Oncol; 2010 Aug; 11(8):753-62. PubMed ID: 20619739 [TBL] [Abstract][Full Text] [Related]
17. Polymorphisms in cyclooxygenase-2 and epidermal growth factor receptor are associated with progression-free survival independent of K-ras in metastatic colorectal cancer patients treated with single-agent cetuximab. Lurje G; Nagashima F; Zhang W; Yang D; Chang HM; Gordon MA; El-Khoueiry A; Husain H; Wilson PM; Ladner RD; Mauro DJ; Langer C; Rowinsky EK; Lenz HJ Clin Cancer Res; 2008 Dec; 14(23):7884-95. PubMed ID: 19047118 [TBL] [Abstract][Full Text] [Related]
18. High let-7a microRNA levels in KRAS-mutated colorectal carcinomas may rescue anti-EGFR therapy effects in patients with chemotherapy-refractory metastatic disease. Ruzzo A; Graziano F; Vincenzi B; Canestrari E; Perrone G; Galluccio N; Catalano V; Loupakis F; Rabitti C; Santini D; Tonini G; Fiorentini G; Rossi D; Falcone A; Magnani M Oncologist; 2012; 17(6):823-9. PubMed ID: 22584434 [TBL] [Abstract][Full Text] [Related]
19. Comparison of the prevalence of KRAS-LCS6 polymorphism (rs61764370) within different tumour types (colorectal, breast, non-small cell lung cancer and brain tumours). A study of the Czech population. Uvirova M; Simova J; Kubova B; Dvorackova N; Tomaskova H; Sedivcova M; Dite P Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2015 Sep; 159(3):466-71. PubMed ID: 26077004 [TBL] [Abstract][Full Text] [Related]